NSE: SAILIFE · BSE: 544306 · ISIN INE570L01029
Sai Life Sciences Limited stock analysis
Sai Life Sciences Limited ranks #224 in the TickerSutra evidence-ranked universe with a score of 69/100 and 91% data confidence. The latest captured fundamentals show ROCE of 19.6%, quarterly sales growth of 11.7% and quarterly profit growth of 21.2%.Watchlist candidate
INVESTMENT EVIDENCE
What supports—and challenges—the thesis
Evidence in favour
- Low debt/equity of 0.12×
- Strong CFO/EBITDA of 0.8×
- 21.7% three-year sales CAGR
- Institutional ownership is rising
- CWIP indicates an active capacity pipeline
- No promoter shares are reported as pledged
Risks and constraints
- Valuation is above 40× earnings
Still unresolved: Related-party exposure · Broad media sentiment
FINANCIAL TRAJECTORY
Recent operating history
| Period | Revenue | Operating profit | Net profit | Operating margin |
|---|---|---|---|---|
| 2022 | ₹870cr | ₹126cr | ₹6cr | 15.0% |
| 2023 | ₹1,217cr | ₹169cr | ₹10cr | 14.0% |
| 2024 | ₹1,465cr | ₹287cr | ₹83cr | 20.0% |
| 2025 | ₹1,695cr | ₹410cr | ₹170cr | 24.0% |
| 2026 | ₹2,192cr | ₹634cr | ₹349cr | 29.0% |
| TTM | ₹2,250cr | ₹658cr | ₹362cr | 29.0% |
EXCHANGE EVENT TRIGGERS
Latest corporate disclosures
Closure of Trading Window relating to Unaudited Financial Result for the Second Quarter and Half Year Ending on 30th September 2026
RoutineAllotment of SecuritiesNSE · 18 Sept 2026 · Structured filingSai Life Sciences Limited has informed the Exchange regarding allotment of 24000 securities pursuant to ESOP/ESPS at its meeting held on September 18, 2026
Sai Life Sciences Limited has informed the Exchange regarding allotment of 24000 securities pursuant to ESOP/ESPS at its meeting held on September 18, 2026
Open original XBRL sourceAllotment of 24,000 Equity Shares having Face Value of Rs. 1/- as per Company''s ESOP Plan
MANAGEMENT COMMENTARY
Signals from filed documents
EBITDA increased by 55.6% YoY to H661 Cr. EBITDA margin expanded by 508 basis points to 30.1% in FY 2025–26 from 25.1% in FY 2024–25, mainly due to operating leverage on employee costs, material margin and other expenses. Depreciation and amortisation expense increased to H167 Cr.
Changes in the global funding environment can influence outsourcing demand and project pipelines. Sustained pricing pressure could affect margins, profitability and cash flows, potentially limiting the Company’s ability to invest in capacity expansion, technology enhancement, innovation and talent development. Execution delays could result in project losses, reduced customer confidence, lower business opportunities a
Our global delivery model combines proximity to key innovation hubs in the United States and the United Kingdom with large-scale research, development and manufacturing capabilities in India. This enables a seamless transition from early-stage research to commercial production. Backed by scientific rigour, advanced infrastructure and a highly skilled workforce, we strengthen long-term partnerships, expand capabilitie
Changes in the global funding environment can influence outsourcing demand and project pipelines. Sustained pricing pressure could affect margins, profitability and cash flows, potentially limiting the Company’s ability to invest in capacity expansion, technology enhancement, innovation and talent development. Execution delays could result in project losses, reduced customer confidence, lower business opportunities a
Employee grievances, industrial disputes, lower workforce morale and business disruptions. Skills gaps, reduced innovation, lower productivity and inability to meet evolving customer or regulatory requirements. Discrimination claims, reduced innovation, talent retention issues and reputational impacts.
Performance Evaluation Framework The evaluation framework for the Board of Directors has been designed in accordance with the requirements of the Act and LODR Regulations and in consonance with the guidance note on Board evaluation issued by SEBI. The framework has been approved by the Board based on the recommendation of the Nomination and Remuneration Committee. The objective of the framework is to ensure corporate
The results are also uploaded on the website of the Company at https:/ /sailife.com/ financial-information/ and is published in leading newspapers such as Business Standard and Mana Telangana. Investor Calendar and Presentation The Company regularly conducts/ participates in Investor Conferences, Analysts/ Institutional Investors' Meet, Investor Roadshow to discuss its performance. The schedule of the same is intimat
HOW TO READ THIS PAGE
Evidence, freshness and limitations
What does the TickerSutra score mean?
The score ranks captured evidence across financial quality, growth, moat and margins, regulatory catalysts, governance, institutional trend and valuation comfort. It is a research-prioritization tool—not a buy recommendation or price target.
Which sources support this page?
Financial history, ownership and pledge data, NSE and BSE filings, annual reports and available earnings-call transcripts are combined here. Use the source trail and original exchange document before relying on a decision-critical fact.
Why can an item be unresolved?
Unresolved means the current captured source window did not provide enough evidence for that check. It does not establish that a risk or relationship is absent.
Maintained by TickerSutra Research · Snapshot updated 29 Sept 2026 · Read the methodology · Read the disclaimer
DIRECTOR & BUSINESS NETWORK
Loading corporate intelligence
Loading universe coverage and exchange-backed evidence…